Hikma Pharmaceuticals announces a pharma partnership with Eisai for the distribution of Fycompa.
Fycompa (perampanel) is Eisai’s first-in-class epilepsy treatment, in the Middle East.
The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015.
Perampanel is the only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures.
Countries covered by the five year partnership will include the Kingdom of Saudi Arabia, United Arab Emirates, Jordan, Kuwait, Bahrain, Oman, Qatar, Sudan, Iraq, Libya and Yemen
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Eisai
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity